Zacks Investment Research upgraded shares of ROCKWELL MED (RMTI) from UNDERPERFORM to NEUTRAL on September 17, 2013, with a target price of $10.50.
Rockwell Medical Technologies, Inc. manufactures hemodialysis concentrates and dialysis kits, and sells, distributes and delivers such concentrates and dialysis kits, as well as other ancillary hemodialysis products, to hemodialysis providers in the United States. Hemodialysis is a process which is able to duplicate kidney function in patients whose kidneys have failed to function properly.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ROCKWELL MED (RMTI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment